A BS TRACT: Background: The characteristic progression of Lewy pathology in Parkinson's disease likely involves intercellular exchange and the accumulation of misfolded α-synuclein amplified by a prion-like selftemplating mechanism. Silencing of the α-synuclein gene could provide long-lasting disease-modifying benefits by reducing the requisite substrate for the spreading aggregation. Objectives: As a result of the poor penetration of viral vectors across the blood-brain barrier, gene therapy for central nervous system disorders requires direct injections into the affected brain regions, and invasiveness is further increased by the need for bilateral delivery to multiple brain regions. Here we test a noninvasive approach by combining low-intensity magnetic resonance-guided focused ultrasound and intravenous microbubbles that can transiently increase the access of brain impermeant therapeutic macromolecules to targeted brain regions. Methods: Transgenic mice expressing human α-synuclein were subjected to magnetic resonanceguided focused ultrasound targeted to 4 brain regions (hippocampus, substantia nigra, olfactory bulb, and dorsal motor nucleus) in tandem with intravenous microbubbles and an adeno-associated virus serotype 9 vector bearing a short hairpin RNA sequence targeting the α-synuclein gene. Results: One month following treatment, α-synuclein immunoreactivity was decreased in targeted brain regions, whereas other neuronal markers such as synaptophysin or tyrosine hydroxylase were unchanged, and cell death and glial activation remained at basal levels.
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Conclusions: These results demonstrate that magnetic resonance-guided focused ultrasound can effectively, noninvasively, and simultaneously deliver viral vectors targeting α-synuclein to multiple brain areas. Importantly, this approach may be useful to alter the progression of Lewy pathology along selected neuronal pathways, particularly as prodromal PD markers improve early diagnoses. © 2018 International Parkinson and Movement Disorder Society Lewy pathology suggests that the initial appearance of α-syn aggregates in the central nervous system (CNS) occurs in the dorsal motor nucleus of the vagus (DMN) in the lower brain stem and in the olfactory bulb (OB), followed by a rostral progression of pathology into the midbrain and cerebral cortex. [7] [8] [9] These early manifestations of synucleinopathy correspond to prodromal nonmotor features of PD, including constipation, as a result of impaired vagal innervation of the gastrointestinal tract, and a loss of olfaction. 10 The spreading Lewy pathology is linked to α-syn's ability to self-template in a manner similar to prions.
11-14 α-Syn can adopt stable conformations with high beta-sheet content, and misfolded variants can confer their structure onto additional α-syn molecules. In multiple experimental cell and animal models, α-syn pathology spreads to nearby cells or along neuronal tracts following inoculation with either fibrillar α-syn or synucleinopathy-sourced brain homogenates. [15] [16] [17] [18] [19] [20] [21] [22] The underlying process, initially postulated to explain Lewy pathology within fetal grafts implanted in PD patients, 23, 24 implicates a general spreading cascade whereby the exchange of misfolded α-syn is coupled to its interaction with native α-syn in recipient neurons. 25 The inherent requirement for α-syn expression in recipient neurons for permissive templating is consistent with PD genetics showing that elevated α-syn expression by gene multiplication raises the risk for PD. [26] [27] [28] Conversely, therapeutic down-regulation of α-syn expression may be a viable approach to delay or block spreading pathology in PD. 29 Several studies have reported α-syn knockdown in rodents or primates [30] [31] [32] [33] [34] [35] [36] [37] [38] and as protection against dopaminergic degeneration induced by either rotenone or α-syn fibrils. [39] [40] [41] However, a key challenge to adapting putative therapeutics for clinical use is the low penetrability of the bloodbrain barrier (BBB) to molecules larger than 400 Da and of poor lipid solubility, thereby limiting the effectiveness of systemically delivered immuno-or gene therapies for brain disorders. 42 CNS entry of therapeutic molecules such as immunoglobulin, growth factors, or nonviral gene sequences are enhanced by conjugation to brain-penetrant ligands (molecular Trojan horse) recognized by an endogenous transporter. 43 For example, encapsulation of α-syn small interfering ribonucleic acid (siRNA) into exosomes labeled with a brain-targeting viral peptide 34 or direct conjugation to a monoamine reuptake inhibitor 37 reduced α-syn expression in brain neurons. One limitation of nonviral gene expression is its transient effect, such that treatments must be repeated to maintain gene regulation.
Stable gene expression lasting more than a decade can be safely achieved with viral vectors, 44 ,45 although brain delivery requires intracerebral injections, which are invasive and carry risks of infection, hemorrhage, and neuronal damage around the injection site. 46 Moreover, the practicality of intracerebral injections is diminished by the need for multiple injections to cover an entire brain region or bilateral coverage in multiple brain regions. Alternatively, transcranial magnetic resonance (MR)-guided focused ultrasound (FUS) combined with microbubbles injected into the bloodstream can locally and transiently increase the permeability of the BBB for several hours after sonication. 47 This approach permits brain targeted delivery of systemically administered therapeutics, such as immunoglobulin or viral vectors, efficiently across the BBB without invasive surgery. [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] Here, we use FUS to deliver a virally expressed short hairpin RNA (shRNA) to silence the α-syn gene in multiple discrete brain regions that are known to develop Lewy pathology in PD. Our study demonstrates the feasibility of simultaneous modulation of α-syn expression in distal brain regions without multiple invasive procedures.
Methods

Virus
Recombinant adeno-associated virus serotype 9 (AAV9) was used to express shRNA targeting human α-syn to knockdown human α-syn gene expression in our transgenic mouse model. Plasmids containing a silencing sequence targeting nucleotides 299 to 309 of the human α-syn gene (AAV9-hSNCA-shRNA) 33 were generously provided by Dr. Martha C. Bohn (Northwestern University, Chicago, Illinois). Control plasmids contain a scrambled (Scr) sequence of the same nucleotides (AAV9-ScrshRNA). Both vectors used in this study, and as previously reported, 59 contain short mir-30 microRNA insertions flanking the 5' and 3' ends of the silencing sequence, which can reduce cell death associated with hSNCA-shRNA. Upstream to the silencing cassette included the cytomegalovirus promoter, a reporter turbo green fluorescent protein (turboGFP) sequence, and an internal ribosome entry site for bicistronic expression. Single-stranded recombinant AAV9 (rAAV9) viruses expressing either hSNCA-or the Scr-shRNA were produced by Virovek, Hayward, CA. 
Animals
Transgenic (Tg) mice (3-4 months) lacking endogenous murine α-syn but expressing wild-type human α-syn were used in this study. 60, 61 Pan-neuronal expression of the human Tg α-syn is driven by the hamster prion promoter. [62] [63] [64] [65] [66] [67] [68] [69] Brain α-syn protein levels are 1-to 1.5-fold of nonTg wild-type animals, and the Tg animals do not manifest behavioral changes or brain abnormalities at the ages studied. The 8 Tg mice received FUS targeting the hippocampus (HC) and substantia nigra (SN), and another 8 Tg mice received FUS targeting the OB and DMN. These FUS-targeted groups were subdivided into 2 virus treatment groups (n = 4 per group): AAV9-Scr-shRNA or AAV9-hSNCA-shRNA. Animal procedures were carried out in compliance with the Canadian Council on Animal Care and the Animals for Research Act of Ontario.
MR-guided FUS
Mice were anesthetized with isoflurane, and a 26-gauge catheter was inserted into the tail vein. Mice were secured on an MRI-compatible sled and imaged using a 7.0 T MRI (BioSpin 7030; Bruker, Billerica, MA, USA). Presonication T2-weighted scans were used to target ultrasound foci. In 1 set of animals (n = 8), FUS was targeted to the HC and the ipsilateral SN. In a second set of animals (n = 8), FUS was targeted bilaterally to the OB and DMN. FUS was conducted using the RK100 system (FUS Instruments Inc., Toronto, ON, Canada). Ultrasound waveforms were generated using a spherically focused transducer (1.68 MHz, 75 mm diameter, 60 mm radius of curvature). A polyvinylidene difluoride hydrophone was positioned in the centre of the transducer, as illustrated in Figure 1A .
At the start of sonication, Definity microbubbles (0.02 mL/kg; Lantheus Medical Imaging, North Billerica, MA, USA) were injected via the tail vein. Standard BBB disruption parameters were used for sonication (10-millisecond bursts, 1-Hz pulse repetition frequency, 120-second duration). The applied acoustic pressure was incrementally increased with each pulse. Once subharmonic emissions were detected, the acoustic pressure was dropped by 50% and maintained for the rest of sonication, as described. 70 The peak pressure required for BBB opening was averaged across the focal spots per animal to calculate the mean peak pressure for each animal.
Immediately following FUS, a gadolinium-based MRI contrast agent (0.2 mL/kg Gadovist; Schering AG, Berlin, Germany) was injected via the tail vein and T1 weighted scans were obtained to assess BBB permeability. Mice subsequently received the viral solution in saline via the tail vein catheter and 200 μL of saline to facilitate transfer of the virus into the bloodstream.
The relative enhancement for each animal was calculated as pixel intensity in a 2 mm × 2 mm region on the postsonication T1-weighted MR images normalized to the intensity in a reference region of the brain. The enhancement values were averaged over all ultrasound foci per animal using a custom program (Matlab; MathWorks, Natick, Massachusetts).
Immunohistochemistry
At 1 month postsonication, the mice were deeply anesthetized with a mixture of ketamine (150 mg/kg) and xylazine (10 mg/kg). The animals were transcardially perfused with saline and fixed with 4% paraformaldehyde in 0.1 M phosphate buffer. Whole brains were sectioned axially at 40 μm using a sliding microtome.
For detection of transgene expression, free-floating brain sections were incubated in 10 mM sodium citrate buffer (pH 6.0) for 30 minutes at 80 C and then in blocking solution (5% goat serum, 0.25% Triton X-100 in Phosphate-buffered saline (PBS)) for 2 hours at room temperature (RT). The sections were incubated with anti-turboGFP antibody (PA5-22688, 1:500; Thermofisher Scientific, Waltham, MA, USA) for 72 hours at 4 C and then a secondary antibody for 2 hours at RT, followed by 4'6'-diamidino-2-phenylindole (DAPI, D9542, 1:10 000; Sigma-Aldrich, St. Louis, MO, USA) in PBS for 10 minutes at RT.
To evaluate the extent of α-syn knockdown in the HC and SN, triple labeling for α-syn, synaptophysin, and tyrosine hydroxylase (TH) was performed, while α-syn, synaptophysin, and choline acetyltransferase was performed for the OB and DMN. The sections were incubated in blocking solution at RT for 2 hours, followed by anti-α-syn (32-8100, 1:1000; Invitrogen, Carlsbad, CA), antisynaptophysin (ab52636, 1:250; Abcam, Cambridge, UK), and anti-TH (ab76442, 1:1000; Abcam) primary antibodies for 72 hours at 4 C. The sections were incubated in secondary antibodies for 2 hours, followed by DAPI for 10 minutes at RT.
To detect neuronal cell death associated with shRNA delivery, terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate (dUTP)-fluorescein nick-end labeling (TUNEL), cleaved caspase-3, and neuronal nuclei immunofluorescent colabeling was evaluated. Briefly, TUNEL-positive cells were detected with an in situ cell death detection kit (DeadEnd Flurometric TUNEL system; Promega, Madison, WI, USA), according to the supplier's instructions. The sections were incubated in blocking solution (10% goat serum, 0.3% Triton X-100) for 2 hours at RT, and then for 24 hours at 4 C with primary antibodies against cleaved caspase-3 (9661S, 1:300; Cell Signaling Technology, Danvers, MA, USA) and neuronal nuclei (ABN90, 1:500; Millipore, Temecula, CA, USA), followed by secondary antibodies for 24 hours at 4 C. To characterize the immune response to viral gene therapy, including the activation of glia, we performed double immunolabeling with ionized calcium-binding adapter molecule 1 (Iba-1) and glial fibrillary acidic protein (GFAP), for microglia and astrocytes, respectively. The sections were incubated in 10 mM sodium citrate buffer (pH 6.0) for 30 minutes at 80 C and then in blocking solution (5% donkey serum, 0.25% Triton X-100, PBS) for 2 hours at RT. The sections were incubated with anti-Iba-1 antibody (019-19741, 1:1000; Wako Chemicals, Richmond, VA, USA) and anti-GFAP (NB100-53809, 1:1000; Novus Biologicals, Littleton, CO, USA) for 24 hours at 4 C followed by secondary antibodies for 2 hours and DAPI for 10 minutes at RT.
Imaging and Quantification
Serial sections were processed in parallel and the regions of interest were applied to 4 serial sections throughout the HC, SN, OB, and DMN, as defined using mouse stereotaxic coordinates. 71 All images shown were acquired using a Nikon A1 laser scanning confocal microscope (20 × and 60 × magnification objectives) coupled to NIS-Elements software (Nikon Instruments, Melville, NY, USA). A Z-series of 0.7 μm optical section thickness were merged. All quantification of α-syn, synaptophysin, and TH immunoreactivity was performed using images acquired at 20 × magnification on a Zeiss spinning disk microscope coupled to the PV camera (Zeiss Axio Observer.Z1) and Zen software (Carl Zeiss, Oberkochen, Germany). Tiled Z-stack images were obtained with 0.7 μm optical section thickness and projected to generate maximum intensity images. Signal intensity was examined in regions of interest at sonicated and corresponding non-onicated structures in the brain. Pixel densitometry was analyzed with ImageJ software (National Institutes of Health, Bethesda, Maryland).
Statistical Analysis
Prism software (GraphPad Software Inc., San Diego, CA, USA) was used for statistical analysis and graph generation. All graphs are presented as mean ± standard error of the mean. Statistical significance was set at P < .05. Power analyses were performed using G*Power software. 72 
Results
MRI Enhancement Confirms BBB Permeability in Sonicated Brain Regions
FUS was targeted using T2-weighted MRI scans either unilaterally to the HC and SN in 1 cohort of animals or bilaterally to the OB and DMN in a second cohort (Fig. 1B,C) . Postsonication, gadolinium enhancement was measured from T1-weighted images of targeted brain areas (Fig. 1D-G) , reflecting the relative amount of FUSinduced BBB opening. 73 We found no significant difference in enhancement level between AAV9-hSNCAshRNA and AAV9-Scr-shRNA treated animals, indicating comparable FUS-mediated increase in BBB permeability between the treatment groups (Fig. 1H,J) . Normalized to the reference region, the mean increase in voxel intensity in sonicated regions was 43% ± 17% and 47% ± 13% in the AAV9-hSNCA-shRNA and AAV9-Scr-shRNA injected groups, respectively (P = .62).
Similarly, there was no difference in the mean acoustic energy delivered to the FUS-targeted regions between treatment groups (Fig. 1I,K) . For the AAV9-hSNCA-shRNA and AAV9-Scr-shRNA groups, respectively, the mean peak pressure during sonication was 1.0 ± 0.2 and 1.1 ± 0.2 (P = .52). These data suggest that consistent BBB opening was achieved by using similar acoustic pressures in both treatment groups.
Reduction in α-Syn Expression After FUSMediated Delivery of Silencing Vector
The AAV9 vectors contained a reporter turboGFP sequence to verify transgene expression and location to FUS-targeted brain regions. All sonicated areas showed immunoreactivity to turboGFP (Fig. 1L-W) . In contrast, there was no turboGFP expression in corresponding contralateral regions of brains that were not targeted by FUS. These results confirm the poor penetration of the virus across an intact BBB at an intravenous dose of 1.25 × 10 10 VG/g and that AAV9 delivery to the brain is selectively increased by FUS application. Varying levels of turboGFP expression were evident between brain areas, possibly reflecting regional neuronal versus nonneuronal populations and differences in afferent projections containing nerve terminals enriched in α-syn and presynaptic marker synaptophysin. In adult mice, AAV9 displays neuronal tropism, particularly when delivered to the brain and spinal cord using intraparenchymal injections or systemic administration combined with FUS. 48, 51, [74] [75] [76] [77] Here, the amount and localization of turboGFP-positive cells found in the hippocampal formation are comparable to previously reported using scAAV9-GFP. 51 The targeting of the OB, SN, and DMN also results in a subpopulation of neurons expressing turboGFP and suggest that α-syn is suppressed within that subpopulation of neurons transduced. One month following FUS-mediated delivery of the AAV9 vectors, α-syn immunoreactivity was observed in the FUS-targeted regions receiving the control ScrshRNA ( Fig. 2-3; red) . The α-syn expression was a diffuse, punctate pattern matching that of synaptophysin, consistent with its preferentially presynaptic localization as observed in previous studies. [78] [79] [80] [81] [82] [83] [84] [85] In comparison, FUS-targeted regions of animals treated with hSNCA-shRNA had lower α-syn immunoreactivity.
Synaptophysin expression was similar between the 2 treatments (Fig. 2E,3E ), suggesting that synaptic integrity remains unaltered following FUS gene delivery. Therefore, to account for anatomical variations in the regions of interest, we normalized the intensity of α-syn immunofluorescence to that of synaptophysin (Figs. 2F-G and 3F-G) . Regions of interest in the SN and DMN were identified by the presence of dopaminergic (TH positive) and cholinergic (choline acetyltransferase positive) soma (Supplemental Fig. 1 ). Relative to FUS-mediated delivery of AAV9-ScrshRNA, we found a significant decrease in the α-syn/ synaptophysin ratio following AAV9-hSNCA-shRNA treatment in the FUS-targeted HC (P = .021), SN (P = .012), and OB (P = .018). Similarly, we noted that α-syn levels in the DMN were 1.6 ± 0.3 and 2.6 ± 0.4 when treated with AAV9-hSNCA-shRNA and AAV9-Scr-shRNA, respectively (P = .081, t-test, n = 4).
Based on these results, a power analysis reveals that sample sizes of 6 animals per treatment group have an 80% power to detect differences with a significance level of .05 (2-tailed).
There are reports of a decline in nigral TH expression following suppression of α-syn in the SN, 32, 36, 38 raising the possibility of neurotoxicity associated with low α-syn levels. However, despite the 60% reduction in α-syn, there was no change in TH immunoreactivity in the SN (Fig. 4) , whether in comparison to the control shRNA treatment (P = .181) or to the contralateral hemisphere (P = .773).
Absence of Cell Death or Glial Activation 1 Month Following FUS Treatment
As measures of potential neuronal damage, we evaluated markers of cell death and glial activation in brain areas targeted with FUS and the AAV9 vectors. There was no discernible increase in TUNEL or cleaved caspase-3 staining as a result of FUS or α-syn knockdown in any brain region evaluated (Fig. 5A-L) . The OB displayed some neuronal apoptosis in all groups (Fig. 5G-I) , which is related to normal granule cell turnover. [86] [87] [88] Moreover, the distribution and intensity of glial markers including astrocytes (GFAP) and microglia/macrophages (Iba-1) [89] [90] [91] were comparable in FUS-targeted areas between mice treated with Scr-shRNA or hSNCAshRNA, and hSNCA-shRNA without FUS ( Fig. 5M-X ; Supplemental Figs. 2-5 ). These results are consistent with previous studies that reported a transient increase in glial activation and inflammatory markers after FUS treatment using parameters that minimized cell death and a subsequent return to baseline levels. 50, 55, [92] [93] [94] [95] Consistent with the unchanged TH staining in Figure 4 , the absence of cell death markers after 1 month of transgene expression further indicates a lack of neurotoxicity associated with α-syn gene silencing.
Discussion
There are multiple difficulties associated with pharmacological treatment of CNS disorders. Primary among these is the inability of many drugs to cross the BBB at therapeutic levels. This limitation can be circumvented with transcranial MR-guided FUS, which increases the permeability of the BBB locally and transiently for up to 6 hours when combined with intravenous microbubbles. 96 We and others have shown that FUS is a safe and practical technology for the therapeutic delivery of macromolecules, genes, and cells into the CNS. 50, [52] [53] [54] [55] 57 It is effective in a broad spectrum of species, from rodents to humans, to target selectively brain regions as small as 1 to 2 mm to an entire hemisphere.
In this study, we show that a single intravenous injection of AAV9 encoding α-syn inhibitory RNA, delivered to the brain using FUS in combination with microbubbles, is sufficient to decrease α-syn expression in FUS-targeted brain regions. Based on the Braak histopathological staging of PD, we sonicated the OB, DMN, SN, and HC, which represent a spectrum of brain regions affected from early to late PD. 8, 97, 98 The FUS-mediated increase in BBB permeability was confirmed by the diffusion of MRI contrast agent gadolinium around target areas and by the robust expression of the reporter turboGFP at 1-month posttreatment, neither of which was detectable in nonsonicated hemispheres. Each FUS focal spot demarcated by gadolinium enhancement (Fig. 1D,F) is approximately 1 mm in diameter laterally and 3 to 4 mm along the beam, which is challenging to dissect without contamination from surrounding tissue expressing normal levels of α-syn. Therefore, to validate the FUS-mediated knockdown of α-syn in multiple discrete brain areas, we relied on immunofluorescence, which offers superior spatial resolution compared to western blotting to detect changes in protein levels. The α-syn immunoreactivity was decreased in FUS-targeted areas of animals treated with hSNCA-shRNA relative to control Scr-shRNA. The overall extent of the α-syn knockdown varied depending on the brain region, as transgene expression is influenced by local differences in transduction efficiency, cell-specific tropism, and the ratio of cell soma to axons. 99 Transduction efficiency was consistent with our previous reports, 48, 51 and the graded expression of turboGFP in cells within each brain region implies a corresponding range of α-syn knockdown in those cells. In the current study, FUS targeting was intentionally limited to small brain volumes to establish proof of concept. FUS exposure to broader brain areas, 51 coupled with improvements in AAV vectors, including capsid, promoter, and transgene, could further enhance therapeutic efficacy. Nevertheless, the decrease was clearly selective for α-syn expression because synaptophysin, which is also highly expressed in nerve terminals, was unchanged by the shRNA treatment and was therefore used to normalize α-syn within each region of interest. The α-syn shRNA reduced α-syn expression by at least 50% (P < .05) in the HC, SN, and OB, and by 40% (P = .08) in the DMN. A power analysis indicates that a total of 6 animals per treatment group would be required to reach the recommended power level of 0.80 with α set to 0.05 (1-tailed). Previous reports using stereotaxic injections to deliver α-syn interfering RNA or antisense oligonucleotides also effectively reduced transgenic and endogenous brain α-syn in rodents and primates. 30, 31, 33, 34, [39] [40] [41] Although the 35% to 60% knockdown in α-syn expression in those studies had minimal adverse effects, higher levels of α-syn gene silencing appeared to induce some nigral toxicity causing a loss of TH expression. 32, 36, 38 In contrast, we did not detect any loss of TH immunoreactivity in the SN following sonication and α-syn shRNA, either in comparison to the sonicated SN with control shRNA or to the contralateral nonsonicated SN in hSNCA-shRNA injected animals. Moreover, markers of apoptotic cell death or glial activation were not notably changed 1 month after the virus or FUS treatments, consistent with our previous studies. 50, 94, 95 Idiopathic PD is an ideal neurodegenerative disorder for gene therapy; α-syn pathology, neurodegeneration, and dopamine loss are confined to discrete brain regions, and clinical motor symptoms are quantifiable. As the identification of prodromal motor and nonmotor symptoms increasingly refine early diagnoses of PD, 10, [100] [101] [102] [103] [104] drug delivery to appropriate brain regions will be relevant for initiating disease-modifying treatments as early as possible. The ability to target specific brain regions for gene therapy, as shown here, may prevent spreading Lewy pathology following α-syn knockdown and also rescue failing neurons when combined with regeneration strategies using growth factors. Previous phases I and II clinical trials used viral vectors to express growth factors (neurturin, Glial cell line-Derived Neurotrophic Factor (GDNF)) or increase dopamine biosynthesis (TH, aromatic L-amino-acid decarboxylase, and Guanosine triphosphate (GTP) cyclohydrolase-1). [105] [106] [107] These trials involved small numbers of patients with fairly advanced disease and revealed only transient or modest benefits despite long-lasting and well-tolerated transgene expression. Several current phases I and II trials are targeting α-syn (NPT200-11, Neuropore Therapeutics, San Diego, CA, USA; PRX002, Biotech Prothena, Dublin, Ireland; AFFITOPE-PD01A, AFFiRiS AG, Vienna, Austria; BIIB-054, Biogen, Cambridge, MA, USA; anti-aggregant EGCG, Ludwig Maximillians University, Munich, Germany; ClinicalTrials.gov). Whether these treatments, in single or combination therapies, will provide sufficient neuroprotection and regeneration for clinical improvement at early disease stages remains to be determined. Nevertheless, it is likely that enhanced delivery across the BBB will be beneficial therapeutically. For example, recent FUS-mediated GDNF expression in the rat brain was shown to protect against 6-hydroxydopamine toxicity, 56, 58 and a phase I clinical trial to evaluate low intensity FUS in Alzheimer's patients has recently been completed (NCT02986932, ClinicalTrials.gov). 108 Our results represent an opportunity to alter the infiltration of α-syn pathology into the CNS prior to its effects on the SN. To our knowledge, not only is this the first report targeting the OB and the DMN regions for α-syn gene silencing but also that multiple distal and discrete brain regions were targeted simultaneously. One limitation of our study is that we did not assess therapeutic benefits of α-syn knockdown. Studies are underway to determine the therapeutic window for neuroprotection and the rescue of motor symptoms after initiation of Lewy pathology in α-syn fibril seeding models. We anticipate that the choice of regimen and brain region will be aided by ongoing advances in prodromal biomarkers and imaging diagnostics. The use of FUS to deliver therapeutics in a targeted manner could open a range of opportunities for the treatment of synucleinopathies, particularly with complementary approaches including gene silencing, immunotherapy, anti-aggregants, and growth factors.
